Lobeglitazone
- Generic Name
- Lobeglitazone
- Drug Type
- Small Molecule
- Chemical Formula
- C24H24N4O5S
- CAS Number
- 607723-33-1
- Unique Ingredient Identifier
- MY89F08K5D
- Background
Lobeglitazone is an antidiabetic medication from the thiazolidinedione class of drugs. It primarily functions as an insulin sensitizer by binding and activating Peroxisome Proliferator-Activated Receptors (PPAR) gamma within fat cells. By activating PPAR-gamma and promoting the binding of insulin at fat cells, lobeglitazone thereby has been shown to reduce blood sugar levels, lower hemoglobain A1C (HbA1C) levels, and improve lipid and liver profiles . Unlike Pioglitazone, which is a dual PPAR agonist at PPAR-alpha and PPAR-gamma, Lobeglitazone is a pure PPAR-alpha agonist.
Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
- Indication
Lobeglitazone was approved by the Ministry of Food and Drug Safety (South Korea) in 2013, and is being monitored by postmarketing surveillance until 2019. Lobeglitazone is not approved for use by either the Food and Drug Administration (USA), Health Canada, or by the European Medicines Agency for use in the management of diabetes.
Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety
- Conditions
- Diabetes Type 2
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 99
- Registration Number
- NCT05915949
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT04431687
- Locations
- 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT04334213
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie
- Conditions
- Type 2 Diabetes MellitusInadequate Glucose Control
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 159
- Registration Number
- NCT03770052
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 30
- Registration Number
- NCT02854748
- Locations
- 🇰🇷
Dong A University Hospital, Seo-gu, Busan, Korea, Republic of
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02338921
- Locations
- 🇰🇷
Soo Lim, Seongnam, Gyeonggi, Korea, Republic of
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT02315287
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD
- Conditions
- Type 2 DiabetesNon-alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 38
- Registration Number
- NCT02285205
- Locations
- 🇰🇷
Severance Hospital, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 28
- Registration Number
- NCT02007941
- Locations
- 🇰🇷
The Inje University Busan Paik Hospital, Busan, Korea, Republic of
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2016-07-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 26
- Registration Number
- NCT02005744
- Locations
- 🇰🇷
Yonsei University Severance Hospital, Soeul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.